SEC filings and other documents

SCD therapy delivers improved survival in pediatric AKI and is expanding into adult markets.

Q1 2026 revenue surged 69% as QUELIMMUNE adoption expanded and clinical milestones advanced.

Pediatric success and adult trial progress drive expansion and regulatory momentum.

Revenue and margins soared as QUELIMMUNE adoption grew; SCD therapy advanced in pivotal trials.

Revenue and clinical adoption surged, with robust trial progress and strengthened financials.

QUELIMMUNE SCD shows strong survival benefits in pediatric AKI and advances toward adult market approval.

Q2 revenue up 15%, NEUTRALIZE-AKI trial at 125/200 enrolled, $12.4M equity raised.

SCD therapy targets hyperinflammation in AKI, unlocking a multibillion-dollar market opportunity.

Q1 revenue surged fourfold as clinical and commercial milestones advanced, expanding market potential.

SCD platform targets hyperinflammation, driving growth in large critical care markets.

QUELIMMUNE launch drives early revenue as pivotal adult AKI trial nears interim analysis.

FDA-approved device for pediatric AKI, pivotal adult trial, and strong market growth potential.

Direct sales of QUELIMMUNE and debt elimination position the company for revenue growth.

FDA-approved device for pediatric AKI shows strong results and commercial momentum.

FDA-approved device for pediatric AKI, pivotal adult trial, and strong market growth prospects.

First QUELIMMUNE sales and adult trial progress highlight growth, despite higher net loss.